319例肝病患者持续肾脏替代治疗的管路寿命及影响因素分析

肝脏 ›› 2022, Vol. 27 ›› Issue (8): 898-902.

319例肝病患者持续肾脏替代治疗的管路寿命及影响因素分析

刘海霞, 段忠辉, 赖曼, 徐曼曼, 孟庆华, 陈煜

100069 首都医科大学附属北京佑安医院重症医学科(刘海霞,赖曼),急诊室(段忠辉),肿瘤科(徐曼曼,陈煜),肝病中心四科(孟庆华)

收稿日期:2022-05-08 出版日期:2022-08-31 发布日期:2022-09-30

Circuit lifespan during continuous renal replacement therapy in 319 patients with hepatic insufficiency

LIU Hai-xia¹, DUAN Zhong-hui², LAI Mai¹, XU Man-man³, MENG Qing-hua⁴, CHEN Yu³

1. Department of Critical Care Medicine of Liver Disease, Beijing You'an Hospital, Capital Medical University, Beijing 100069,China;
2. Emergency Department, Beijing You'an Hospital, Capital Medical University, Beijing 100069, China;
3. Department of Medical Oncology, Beijing You'an Hospital, Capital Medical University, Beijing 100069, China;
4. Department of the Forth Wards of Liver Disease, Beijing You'an Hospital, Capital Medical University, Beijing 100069, China

Received:2022-05-08 Online:2022-08-31 Published:2022-09-30

摘要/Abstract

摘要： 目的评估不同抗凝方式对肝功能不全患者持续肾脏替代治疗(continuous renal replacement therapy,CRRT)管路寿命和并发症的影响。方法回顾性分析北京佑安医院近12年进行CRRT治疗的319例肝病患者资料,对比全身肝素、枸橼酸钠局部抗凝与无抗凝对管路寿命和并发症的影响,分析影响管路寿命的危险因素。结果无抗凝的管路寿命为10(6,21)h,肝素抗凝为13(9,23)h(P=0.203),枸橼酸钠局部抗凝为21(11,56)h,较肝素显著延长(P=0.000)。肝素抗凝组的出血发生率为30.8%,显著高于未抗凝组的11.4%和枸橼酸钠抗凝组的4.2%(P=0.000)。枸橼酸钠局部抗凝组总钙/离子钙 >2.5发生率为 25.8%,代谢性酸中毒和代谢性碱中毒发生率分别为16.8%和12.1%,均高于其他2组(P<0.05)。多因素COX比例风险模型回归分析显示,肝衰竭(HR=1.49 ,95%CI:1.16～1.90)和非枸橼酸局部抗凝(HR=0.51,95%CI:0.43～0.62)是肝病患者管路寿命<48 h的危险因素(P<0.005)。结论肝病患者CRRT的管路寿命较短,肝素不能带来临床益处,枸橼酸钠局部抗凝延长管路寿命,但枸橼酸蓄积的发生率增加,肝衰竭和非枸橼酸局部抗凝与管路寿命<48 h相关。

关键词: 肝损伤, 持续肾脏替代治疗, 肝素, 枸橼酸, 管路寿命

Abstract: Objective To evaluates the circuit lifespan and complications of CRRT in patients with hepatic insufficiency using different anticoagulation agents.Methods Retrospective analysis of 319 patients with severe liver injury treated with CRRT in the Department of critical medicine of Beijing You'an Hospital in recent 12 years. The effects of systemic heparin, regional citrate anticoagulation (RCA) and non-anticoagulation on circuit lifespan and complications were analyzed. The risk factors affecting circuit lifespan were analyzed.Results The circuit lifespan without anticoagulation was 10 (6,21) hours and was not prolonged by heparin in patients with hepatic insufficiency [13 (9,23), P=0.203]. The circuit lifespan was 21 (11, 56) h anticoagulated with citrate, which was significantly longer than heparin (P=0.000). Bleeding occurred in 30.8% of patients with heparin, while it was 4.2% in RCA. But, the incidence of total calcium / ionized calcium > 2.5 was 25.8% and the incidence of metabolic acidosis and metabolic alkalosis were 16.8 and 12.1% respectively, which were higher than those in the other two groups (P<0.05). Multivariate Cox regression proportional hazards model analysis revealed that liver failure(HR=1.49 ,95%CI:1.16～1.90) and non-citrate anticoagulation(HR=0.51,95%CI:0.43～0.62) were risk factors for circuit life < 48h.Conclusion The circuit lifespan of CRRT in patients with hepatic insufficiency was shortened. Heparin does not provide clinical benefits. RCA can prolong the circuit lifespan but the citrate accumulation must be cautious about. Liver failure and non-RCA were linked to circuit lifespans < 48 hours in patients with liver disease.

Key words: Hepatic insufficiency, Continuous renal replacement treatment, Heparin, Regional citrate anticoagulation, Circuit lifespan

刘海霞, 段忠辉, 赖曼, 徐曼曼, 孟庆华, 陈煜. 319例肝病患者持续肾脏替代治疗的管路寿命及影响因素分析[J]. 肝脏, 2022, 27(8): 898-902.

LIU Hai-xia, DUAN Zhong-hui, LAI Mai, XU Man-man, MENG Qing-hua, CHEN Yu. Circuit lifespan during continuous renal replacement therapy in 319 patients with hepatic insufficiency[J]. Chinese Hepatolgy, 2022, 27(8): 898-902.

参考文献

[1] Wu CC, Yeung LK, Tsai WS, et al. Incidence and factors predictive of acute renal failure in patients with advanced liver cirrhosis. Clin Nephrol, 2006, 65:28-33.
[2] Betrosian AP, Agarwal B, Douzinas EE. Acute renal dysfunction in liver diseases. World J Gastroenterol, 2007, 13(42):5552-5559.
[3] Chua HR, Baldwin I, Bailey M, et al. Circuit lifespan during continuous renal replacement therapy for combined liver and kidney failure. J Crit Care, 2012, 27(6):744.e7-15.
[4] Agarwal B, Shaw S, Shankar Hari M, et al. Continuous renal replacement therapy (CRRT) in patients with liver disease: is circuit life different? J Hepatol, 2009,51(3):504-509.
[5] Kellum JA,Lameire N,Aspelin P,et al. Kidney disease: Improving global outcomes (KDIGO) acute kidney injury work group: KDIGO clinical practice guideline for acute kidney injury. Kidney Int, 2012 Suppl, 2(1):1-138.
[6] Zhang W, Bai M, Yu Y, et al. Safety and efficacy of regional citrate anticoagulation for continuous renal replacement therapy in liver failure patients: a systematic review and meta-analysis. Crit Care, 2019, 23(1):22.
[7] Khadzhynov D, Schelter C, Lieker I, et al. Incidence and outcome of metabolic disarrangements consistent with citrate accumulation in critically ill patients undergoing continuous venovenous hemodialysis with regional citrate anticoagulation. J Crit Care, 2014, 29:265-271.
[8] Slowinski T, Morgera S, Joannidis M, et al. Safety and efficacy of regional citrate anticoagulation in continuous venovenous hemodialysis in the presence of liver failure: the Liver Citrate Anticoagulation Threshold (L-CAT) observational study. Critical care (London, England), 2015, 19:349.
[9] Sponholz C, Settmacher U, Bauer M, et al. Regional citrate anticoagulation for continuous renal replacement therapy in the perioperative care of liver transplant recipients: a single center experience. Ther Apher Dial, 2015,19:8-15.
[10] Schultheiss C, Saugel B, Phillip V, et al. Continuous venovenous hemodialysis with regional citrate anticoagulation in patients with liver failure: a prospective observational study. Crit Care, 2012, 16(4):R162.
[11] 中华医学会感染病学分会肝衰与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰诊治指南(2018年版). 中华传染病杂志, 2019, 37(1):1-9.
[12] Tan HK, Baldwin I, Bellomo R. Continuous veno-venous hemofiltration without anticoagulation in high-risk patients. Intensive Care Med, 2000, 26(11):1652-1657.
[13] Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med, 2011, 365:147-156.
[14] Kerr R, Newsome P, Germain L, et al. Effects of acute liver injury on blood coagulation. J Thromb Haemost,2003,1:754-759.
[15] Sakr Y. Heparin-induced thrombocytopenia in the ICU: an overview. Crit Care, 2011,15:211.
[16] Klingele M, Stadler T, Fliser D, er al. Long-term continuous renal replacement therapy and anticoagulation with citrate in critically ill patients with severe liver dysfunction. Critical care (London, England), 2017, 21(1):294.
[17] Meier-Kriesche HU, Gitomer J, Finkel K, et al. Increased total to ionized calcium ratio during continuous venovenous hemodialysis with regional citrate anticoagulation. Crit Care Med, 2001, 29:748-752.
[18] Schneider AG, Journois D, Rimmelé T. Complications of regional citrate anticoagulation: accumulation or overload? Crit Care, 2017, 21(1):281.
[19] Thanapongsatorn P, Chaijamorn W, Sirivongrangson P, et al. Citrate pharmacokinetics in critically ill liver failure patients receiving CRRT. Sci Rep, 2022, 2(1):1815.
[20] Schneider AG, Journois D, Rimmelé T. Complications of regional citrate anticoagulation: accumulation or overload? Crit Care, 2017, 21:281.